US generic drugmaker Mylan (Nasdaq: MYL) has launched Telmisartan Tablets USP, 20mg, 40mg and 80mg, the generic version of family-owned German pharma major Boehringer Ingelheim's Micardis tablets.
Mylan received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of hypertension, to lower blood pressure.
US sales of telmisartan in the previously mentioned dosages were around $259.2 million for the 12 months ending March 31, 2014, according to IMS Health quoted by Mylan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze